UTMD at a glance
UTAH MEDICAL PRODUCTS INC (UTMD, SEC CIK 706698) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as October 29, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), UTAH MEDICAL PRODUCTS INC (UTMD) reported revenue of $38.5 million (down 5.8% from FY2024) and net income of $11.3 million. Diluted EPS was $3.48.
- As of September 30, 2026, 23 institutional investment managers tracked by SignalX reported holding UTAH MEDICAL PRODUCTS INC (UTMD) shares worth $74.0 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by CORNWELL KEVIN L on October 29, 2026 of 1,000 shares at $66.75 per share.
- In the last 90 days, UTMD insiders reported 1 open-market purchase ($67K) and 0 open-market sales ($0) on Form 4, a net purchase of $67K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $38.5M
- −5.8% vs prior year
- Insiders · 90 days
- 1 buy · 0 sells
- Net +$67K
- 13F holders
- 23 funds
- $74.0M · −1 vs prior quarter
- Latest 8-K
- Nov 3, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes disclosed from the December 31, 2025 Form 10-K risk factors
- Unknown or currently immaterial risks could materially adversely affect business, financial condition, or operating results
Management Discussion & Analysis
- 3Q revenue $8.621M, down 12.1% YoY from $9.812M, primarily lost PendoTECH and China distributor sales
- Operating margin 32.4% vs 26.6% YoY, gross margin 56.1% vs 57.1%
- Best category Blood Pressure Monitoring and Accessories $1.927M, up from $1.643M; worst Neonatal $1.667M, down from $2.176M
- Cash and investments $85.2M vs $85.8M year-end, with $3.0M dividends, $0.9M repurchases and $5.0M Orion acquisition
- 2026 revenue outlook down 7%-8%, EPS near $3.60 vs $3.48, with slower biopharma replacement sales and Filshie declines as headwinds
AI summary of the UTMD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Quarterly cash dividend increased to $0.315 per share
- Payment scheduled for January 5, 2027
Item 99.1:
- Filing contains only the 8-K signature block, with no substantive operating, financial, or strategic disclosure
- CEO Kevin L. Cornwell signed the report on November 3, 2026
Item EX-99.1: Item EX-99.1
- Quarterly dividend increased 1.6% to $0.315 per share
- Payment scheduled January 5, 2027, for shareholders of record December 17, 2026
Item 99.1:
- Press release covers fiscal 2026 and nine months ended September 30, 2026
- Forward-looking statements address 2026 and beyond, relevant to expectations but subject to execution risks
Item EX-99.1: Item EX-99.1
- 3Q revenue $8.621M, down 12.1%, reflecting lost PendoTECH and China distributor sales plus weaker Filshie demand
- 3Q net income $2.787M, up 5.9%, and diluted EPS $0.876, up 6.8%, supported by lower litigation, amortization and taxes
Item 2.02: Results of Operations and Financial Condition
- Exhibit 99.1 covers UTMD results for the three and nine months ended September 30, 2026
- Press release dated October 22, 2026 includes forward-looking statements for 2026 and beyond
Item 7.01: Regulation FD Disclosure
- Femcare Ltd acquired all common shares of UK-based Orion Medical Supplies Ltd
- Transaction expands Utah Medical Products’ wholly owned subsidiary operations in the United Kingdom
Item EX-99.1: Item EX-99.1
- Femcare acquired all Orion Medical Supplies shares, expanding UTMD’s UK and European medical-device distribution
- Purchase price £3.6 million, funded from cash reserves
AI summaries of UTMD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for UTMD
Don't miss the next UTMD filing
- Alerts as it files. A push when UTMD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut UTMD, by share count.
- Ask anything. An AI agent that reads every UTMD filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| CORNWELL KEVIN L | Buy | Oct 29, 2026 | 1,000 | $66.75 |
| RICHINS PAUL O | G | Jun 29, 2026 | 150 | $73.07 |
| Koopman Brian | G | May 28, 2026 | 50 | $66.27 |
| Koopman Brian | A | Oct 31, 2025 | 500 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $40.9M | $38.5M |
| Gross Profit | - | $24.1M | $22.0M |
| Operating Income | - | $13.6M | $11.4M |
| Net Income | - | $13.9M | $11.3M |
| Gross Margin | - | 59.0% | 57.1% |
| Op. Margin | - | 33.2% | 29.6% |
| Net Margin | - | 33.9% | 29.3% |
| Balance Sheet | |||
| Total Assets | $135.5M | $122.5M | $122.5M |
| Equity | $128.3M | $117.4M | $119.3M |
| ROE | - | 11.8% | 9.5% |
| Per Share | |||
| EPS | - | $3.96 | $3.48 |
| Cash Flow | |||
| Operating CF | - | $14.8M | $14.7M |
| CapEx | - | $230K | $371K |
Source: XBRL data in UTAH MEDICAL PRODUCTS INC (UTMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate UTMD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 23 | $74.0M |
| Q2 2026 | 24 | $71.3M |
| Q1 2026 | 25 | $62.1M |
| Q4 2025 | 24 | $58.6M |
| Q3 2025 | 23 | $67.6M |
| Q2 2025 | 24 | $63.4M |
| Q1 2025 | 21 | $55.5M |
| Q4 2024 | 16 | $57.3M |
- BNY Mellon+13.0K (+38%)
- Dimensional Fund Advisors+5.0K (+2%)
- AQR Capital Management+3.6K (+24%)
- Vanguard Capital Management LLC+2.2K (+2%)
- State Street Corp+1.4K (+2%)
- Morgan Stanley−23.8K (-34%)
- Renaissance Technologies LLC−8.3K (-5%)
- BlackRock−6.1K (-3%)
- T. Rowe Price Group−5.8K (-26%)
- Ameriprise Financial−4.0K (-56%)
- Citadel Advisors LLC+13.9K
- FMR LLC (Fidelity)−18.1K
- U.S. Bancorp−414
Source: 13F-HR filings on SEC EDGAR (aggregated from 180 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
UTMD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 13, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 4 | Oct 29, 2026 | - | - | - |
| 8-K | Oct 22, 2026 | - | Analysis | - |
| 8-K | Aug 31, 2026 | - | Analysis | - |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 23, 2026 | - | Analysis | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | May 29, 2026 | - | - | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 4, 2026 | - | Analysis | - |
| 8-K | Apr 23, 2026 | - | Analysis | - |
| 10-K | Mar 27, 2026 | Dec 31, 2025 | - | |
| 8-K | Jan 29, 2026 | - | - | |
| 4 | Nov 25, 2025 | - | - | |
| 10-Q | Nov 14, 2025 | Sep 30, 2025 | Analysis | |
| 10-Q | Aug 12, 2025 | Jun 30, 2025 | - | |
| SC 13G | Jul 17, 2025 | - | - | |
| 10-Q | May 15, 2025 | Mar 31, 2025 | - | |
| SC 13G | May 14, 2025 | - | - | |
| 10-K | Mar 26, 2025 | Dec 31, 2024 | - | |
| 10-Q | Nov 12, 2024 | Sep 30, 2024 | - | |
| SC 13G | Oct 31, 2024 | - | - | |
| 10-Q | Aug 9, 2024 | Jun 30, 2024 | - | |
| 10-Q | May 10, 2024 | Mar 31, 2024 | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
UTMD SEC filings: frequently asked questions
Are UTMD insiders buying or selling?
In the last 90 days, UTAH MEDICAL PRODUCTS INC (UTMD) officers, directors and 10% owners reported 1 open-market purchase worth $66,750 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold UTMD stock?
As of September 30, 2026, the largest UTAH MEDICAL PRODUCTS INC (UTMD) holders among the 13F filers tracked by SignalX were Dimensional Fund Advisors ($15.1 million), BlackRock ($14.6 million), Renaissance Technologies LLC ($12.4 million), Vanguard Capital Management LLC ($10.1 million), State Street Corp ($4.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was UTMD's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), UTAH MEDICAL PRODUCTS INC (UTMD) reported revenue of $38.5 million (down 5.8% from FY2024) and net income of $11.3 million. Diluted EPS was $3.48. The figures come from the XBRL data in the 10-K.
What did UTMD report in its latest 8-K?
UTAH MEDICAL PRODUCTS INC (UTMD) filed an 8-K on November 3, 2026 reporting Item 8.01 (Other Events). Quarterly cash dividend increased to $0.315 per share.
What are the latest UTMD SEC filings?
UTAH MEDICAL PRODUCTS INC (UTMD) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on October 29, 2026.
What is UTMD's SEC CIK number?
UTAH MEDICAL PRODUCTS INC (UTMD)'s SEC Central Index Key (CIK) is 706698. EDGAR lists every UTMD filing under that number.
Ask anything about UTMD
The research agent reads UTMD's filings, financials, insider trades and 13F holders, then answers with sources.